Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.
Gynecol Oncol. 2011 Jan;120(1):94-100. doi: 10.1016/j.ygyno.2010.09.016. Epub 2010 Oct 17.
The aim of this study was to compare the efficacy of postoperative pelvic radiotherapy plus concurrent chemotherapy with that of extended-field irradiation (EFRT) in patients with FIGO Stage IA2-IIb cervical cancer with multiple pelvic lymph node metastases.
We retrospectively reviewed the medical records of patients with FIGO Stage IA2-IIb cervical cancer who had undergone radical surgery between April 1997 and March 2008. Of these, 55 patients who demonstrated multiple pelvic lymph node metastases were treated postoperatively with pelvic radiotherapy plus concurrent chemotherapy (n=29) or EFRT (n=26). Thirty-six patients with single pelvic node metastasis were also treated postoperatively with pelvic radiotherapy plus concurrent chemotherapy. The recurrence rate, progression free survival (PFS), and overall survival (OS) were compared between the treatment groups.
Pelvic radiotherapy plus concurrent chemotherapy was significantly superior to EFRT with regard to recurrence rate (37.9% vs 69.2%, p=0.0306), PFS (log-rank, p=0.0236), and OS (log-rank, p=0.0279). When the patients were treated with pelvic radiotherapy plus concurrent chemotherapy, there was no significant difference in PFS or OS between the patients with multiple lymph node metastases and those with single node metastases. With regards to grade 3-4 acute or late toxicities, no statistically significant difference was observed between the two treatment groups.
Postoperative pelvic radiotherapy plus concurrent chemotherapy is superior to EFRT for treating patients with FIGO Stage IA2-IIb cervical cancer displaying multiple pelvic lymph node metastases.
本研究旨在比较术后盆腔放疗联合同期化疗与扩展野照射(EFRT)在FIGO 分期 IA2-IIb 期宫颈癌伴多发盆腔淋巴结转移患者中的疗效。
我们回顾性分析了 1997 年 4 月至 2008 年 3 月期间接受根治性手术的 FIGO 分期 IA2-IIb 期宫颈癌患者的病历。其中 55 例患者存在多发盆腔淋巴结转移,术后分别接受盆腔放疗联合同期化疗(n=29)或 EFRT(n=26)治疗。36 例单盆腔淋巴结转移患者术后也接受盆腔放疗联合同期化疗。比较各组患者的复发率、无进展生存期(PFS)和总生存期(OS)。
盆腔放疗联合同期化疗在复发率(37.9% vs 69.2%,p=0.0306)、PFS(log-rank,p=0.0236)和 OS(log-rank,p=0.0279)方面明显优于 EFRT。当患者接受盆腔放疗联合同期化疗时,多发淋巴结转移患者与单发淋巴结转移患者的 PFS 或 OS 无显著差异。对于 3-4 级急性或晚期毒性,两组间无统计学差异。
对于存在多发盆腔淋巴结转移的 FIGO 分期 IA2-IIb 期宫颈癌患者,术后盆腔放疗联合同期化疗优于 EFRT。